drugset / Trial / NCT03569007
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
RandomizedParallel-groupTriple-blindTreatment
Summary
To assess the efficacy and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.
Timeline
- Start
- 2019-05-29
- Primary completion
- 2022-07-21
- Completion
- 2022-07-21
Outcome
Outcome not reported
Stopped: “Trial terminated by Sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Larazotide | Peptide | 0.25 mg | — |
| Comparator | Larazotide | Peptide | 0.5 mg | — |